Asia
Chinese fusion protein company Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push its COVID-19 vaccine into Phase II/III testing and production planning.
Israel’s Health Ministry announced results of a study in the country that showed that the Pfizer-BioNTech COVID-19 vaccine was 98.9% effective at preventing COVID-19 deaths.
It was a busy week for clinical trial announcements. Here’s a look.
BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) could be on its way for regulatory approval as a potential treatment for Waldenström’s macroglobulinemia (WM), a type of non-Hodgkin lymphoma.
Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.
Pfizer’s COVID-19 vaccine data has once again been threatened by hackers. The alleged theft of intellectual property has been laid at the feet of North Korea’s government.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
The origins of COVID-19 continue to be debated in the halls of government, and the findings from a recent investigation conducted by the World Health Organization are unlikely to change many minds as the world continues to grapple with the pandemic.
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
PRESS RELEASES